Substance Use Tools & Resources    

This is an FDA warning that dental problems have been reported with medicines containing buprenorphine that are dissolved in the mouth. Despite these risks, buprenorphine is an important treatment option for opioid use disorder (OUD) and pain, and the benefits of these medicines clearly outweigh the risks.

Contains handouts that clients will need for treatment. Includes handouts for three types of sessions: Individual/ Conjoint, Early Recovery Skills, and Relapse Prevention.

This guideline updates the state of the science on pain research, care, and education with a particular focus on informing the Food and Drug Administration's (FDA's) development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

This toolkit provides guidance and information to hospitals and health systems on how they can partner with patients, clinicians and communities to address the opioid epidemic.

This NIDA policy brief shares evidence-based research on treating opioud use dissorder on pregnancy, including the assessment of methadone and buprenorphine as treatment.

These are slides from a webinar which provided an overview of how drug diversion is a significant risk for patients and institutions and addresses why institutions should have a program in place to detect diversion.

Provides facts about the benefits of using PDMPs for prescribers, pharmacists, patients, and regulatory and law enforcement agencies.

Provides guidance to physicians and pharmacists on buprenorphine regulatory requirements, prescribing, dispensing, and safety recommendations and additional information to improve decision making and promote beneficial outcomes.

A book for clients to record ideas and reminders that will strengthen their recovery and help them stay abstinent.

This manual contains all the materials necessary for a counselor to conduct individual and group sessions using the Matrix Intensive Outpatient Treatment for People with Stimulant Use Disorders (IOP) approach.